A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer

Masaaki Iwatsuki, Koshi Mimori, Takehiko Yokobori, Fumiaki Tanaka, Koichiro Tahara, Hiroshi Inoue, Hideo Baba, Masaki Mori

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Recent progress in chemotherapy with platinum agents has improved clinical outcome in colorectal cancer (CRC), but there are no useful markers to predict the efficacy of such agents. DNA polymerase beta (POLB) mediates the efficacy of chemotherapy through DNA repair machinery. We analyzed the significance of POLB expression in CRC chemotherapy and its potential as a prognostic indicator. Methods: Using microarray, POLB was found to be overexpressed in CRC cells compared with corresponding normal colon epithelial cells. We determined the susceptibility of POLB-suppressed cells to cisplatin and oxaliplatin. We evaluated POLB mRNA expression in 97 CRC cases to determine the clinicopathologic significance of POLB expression. Results: We found the suppression of POLB altered the in vitro susceptibility to cisplatin but not to oxaliplatin. In 97 CRC cases, lymph node metastasis, distant metastasis and TNM classification were significantly greater in the high POLB group than in the low group (P<0.05). Patients with high POLB expression had significantly poorer prognosis than those with low expression (P<0.05). Conclusions: The data indicate POLB is overexpressed in CRC cases with high malignant potential. We suggest POLB could be useful as a predictive marker for selection of patients responsive to cisplatin.

Original languageEnglish
Pages (from-to)261-266
Number of pages6
JournalJournal of Surgical Oncology
Volume100
Issue number3
DOIs
Publication statusPublished - Sep 24 2009

Fingerprint

Platinum
Colorectal Neoplasms
oxaliplatin
Cisplatin
Genes
Drug Therapy
DNA Polymerase beta
Neoplasm Metastasis
Neoplasm Staging
DNA Repair
Patient Selection
Colon
Lymph Nodes
Epithelial Cells
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer. / Iwatsuki, Masaaki; Mimori, Koshi; Yokobori, Takehiko; Tanaka, Fumiaki; Tahara, Koichiro; Inoue, Hiroshi; Baba, Hideo; Mori, Masaki.

In: Journal of Surgical Oncology, Vol. 100, No. 3, 24.09.2009, p. 261-266.

Research output: Contribution to journalArticle

Iwatsuki, Masaaki ; Mimori, Koshi ; Yokobori, Takehiko ; Tanaka, Fumiaki ; Tahara, Koichiro ; Inoue, Hiroshi ; Baba, Hideo ; Mori, Masaki. / A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer. In: Journal of Surgical Oncology. 2009 ; Vol. 100, No. 3. pp. 261-266.
@article{ebe2eddea9d44d9c8bacfe4f66c0cd46,
title = "A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer",
abstract = "Background: Recent progress in chemotherapy with platinum agents has improved clinical outcome in colorectal cancer (CRC), but there are no useful markers to predict the efficacy of such agents. DNA polymerase beta (POLB) mediates the efficacy of chemotherapy through DNA repair machinery. We analyzed the significance of POLB expression in CRC chemotherapy and its potential as a prognostic indicator. Methods: Using microarray, POLB was found to be overexpressed in CRC cells compared with corresponding normal colon epithelial cells. We determined the susceptibility of POLB-suppressed cells to cisplatin and oxaliplatin. We evaluated POLB mRNA expression in 97 CRC cases to determine the clinicopathologic significance of POLB expression. Results: We found the suppression of POLB altered the in vitro susceptibility to cisplatin but not to oxaliplatin. In 97 CRC cases, lymph node metastasis, distant metastasis and TNM classification were significantly greater in the high POLB group than in the low group (P<0.05). Patients with high POLB expression had significantly poorer prognosis than those with low expression (P<0.05). Conclusions: The data indicate POLB is overexpressed in CRC cases with high malignant potential. We suggest POLB could be useful as a predictive marker for selection of patients responsive to cisplatin.",
author = "Masaaki Iwatsuki and Koshi Mimori and Takehiko Yokobori and Fumiaki Tanaka and Koichiro Tahara and Hiroshi Inoue and Hideo Baba and Masaki Mori",
year = "2009",
month = "9",
day = "24",
doi = "10.1002/jso.21275",
language = "English",
volume = "100",
pages = "261--266",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer

AU - Iwatsuki, Masaaki

AU - Mimori, Koshi

AU - Yokobori, Takehiko

AU - Tanaka, Fumiaki

AU - Tahara, Koichiro

AU - Inoue, Hiroshi

AU - Baba, Hideo

AU - Mori, Masaki

PY - 2009/9/24

Y1 - 2009/9/24

N2 - Background: Recent progress in chemotherapy with platinum agents has improved clinical outcome in colorectal cancer (CRC), but there are no useful markers to predict the efficacy of such agents. DNA polymerase beta (POLB) mediates the efficacy of chemotherapy through DNA repair machinery. We analyzed the significance of POLB expression in CRC chemotherapy and its potential as a prognostic indicator. Methods: Using microarray, POLB was found to be overexpressed in CRC cells compared with corresponding normal colon epithelial cells. We determined the susceptibility of POLB-suppressed cells to cisplatin and oxaliplatin. We evaluated POLB mRNA expression in 97 CRC cases to determine the clinicopathologic significance of POLB expression. Results: We found the suppression of POLB altered the in vitro susceptibility to cisplatin but not to oxaliplatin. In 97 CRC cases, lymph node metastasis, distant metastasis and TNM classification were significantly greater in the high POLB group than in the low group (P<0.05). Patients with high POLB expression had significantly poorer prognosis than those with low expression (P<0.05). Conclusions: The data indicate POLB is overexpressed in CRC cases with high malignant potential. We suggest POLB could be useful as a predictive marker for selection of patients responsive to cisplatin.

AB - Background: Recent progress in chemotherapy with platinum agents has improved clinical outcome in colorectal cancer (CRC), but there are no useful markers to predict the efficacy of such agents. DNA polymerase beta (POLB) mediates the efficacy of chemotherapy through DNA repair machinery. We analyzed the significance of POLB expression in CRC chemotherapy and its potential as a prognostic indicator. Methods: Using microarray, POLB was found to be overexpressed in CRC cells compared with corresponding normal colon epithelial cells. We determined the susceptibility of POLB-suppressed cells to cisplatin and oxaliplatin. We evaluated POLB mRNA expression in 97 CRC cases to determine the clinicopathologic significance of POLB expression. Results: We found the suppression of POLB altered the in vitro susceptibility to cisplatin but not to oxaliplatin. In 97 CRC cases, lymph node metastasis, distant metastasis and TNM classification were significantly greater in the high POLB group than in the low group (P<0.05). Patients with high POLB expression had significantly poorer prognosis than those with low expression (P<0.05). Conclusions: The data indicate POLB is overexpressed in CRC cases with high malignant potential. We suggest POLB could be useful as a predictive marker for selection of patients responsive to cisplatin.

UR - http://www.scopus.com/inward/record.url?scp=70249088733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70249088733&partnerID=8YFLogxK

U2 - 10.1002/jso.21275

DO - 10.1002/jso.21275

M3 - Article

VL - 100

SP - 261

EP - 266

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -